Last reviewed · How we verify
Allisartan Isoproxil/Sustained-Release Indapamide
This combination drug lowers blood pressure by blocking angiotensin II receptors (allisartan isoproxil) and inhibiting sodium reabsorption in the kidney (sustained-release indapamide).
This combination drug lowers blood pressure by blocking angiotensin II receptors (allisartan isoproxil) and inhibiting sodium reabsorption in the kidney (sustained-release indapamide). Used for Hypertension.
At a glance
| Generic name | Allisartan Isoproxil/Sustained-Release Indapamide |
|---|---|
| Sponsor | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| Drug class | Angiotensin II receptor blocker / Thiazide-like diuretic combination |
| Target | Angiotensin II type 1 receptor (AT1R) / Sodium-chloride cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Allisartan isoproxil is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from constricting blood vessels and promoting sodium retention. Sustained-release indapamide is a thiazide-like diuretic that inhibits sodium-chloride cotransport in the distal convoluted tubule, promoting sodium and water excretion. Together, these complementary mechanisms provide synergistic antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperuricemia
- Hypokalemia
- Cough
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: